Case Type: Mergers & Acquisitions

Denbury, Inc. (NYSE: DEN), relating to its proposed sale to Exxon Mobil Corp. Under the terms of the agreement, DEN shareholders are expected to receive $89.45 in cash per share they own.

Frequency Therapeutics, Inc. (Nasdaq: FREQ), relating to its proposed merger with Korro Bio, Inc. Under the terms of the agreement, FREQ shareholders are expected to own approximately 8% of the combined company

eMagin Corp. (NYSE: EMAN), relating to its proposed sale to Samsung Display Co., Ltd. Under the terms of the agreement, EMAN shareholders are expected to receive $2.08 in cash per share they own.

Chase Corp. (NYSE: CCF), relating to its proposed sale to an affiliate of investment funds managed by KKR. Under the terms of the agreement, CCF shareholders are expected to receive $127.50 in cash per share they own.

Heritage-Crystal Clean, Inc. (Nasdaq: HCCI), relating to its proposed sale to an affiliate of J.F. Lehman & Co. Under the terms of the agreement, HCCI shareholders are expected to receive $45.50 in cash per share they own.

Neoleukin Therapeutics, Inc. (Nasdaq: NLTX), relating to its proposed merger with Neurogene Inc. Under the terms of the agreement, NLTX shareholders are expected to own approximately 16% of the combined company.

Sculptor Capital Management Inc. (NYSE: SCU), relating to its proposed sale to Rithm Capital Corp. Under the terms of the agreement, Class A SCU shareholders are expected to receive $11.15 in cash per share they own.

Pardes Biosciences, Inc. (Nasdaq: PRDS), relating to its proposed sale to MediPacific, Inc. Under the terms of the agreement, PRDS shareholders are expected to receive at least $2.02 plus an additional cash amount of at most $0.17 in cash per share they own, as well as one non-tradeable CVR.

Sigilon Therapeutics, Inc. (Nasdaq: SGTX), relating to its proposed sale to Eli Lilly and Co. Under the terms of the agreement, SGTX shareholders are expected to receive $14.92 in cash per share they own plus one contingent value right worth up to $111.64.

Immunome, Inc. (Nasdaq: IMNM), relating to its proposed merger with Morphimmune.